Adaptive N=1 Precision Oncology in KRAS-Mutant NSCLC: A Virtual Cohort Simulation of Iterative Treatment Strategies (2026)

By Editorial Team

Abstract

Background: Precision oncology has traditionally relied on population-based evidence, yet tumor heterogeneity and dynamic resistance limit durable responses. N=1 adaptive strategies—where treatment is continuously tailored to an individual patient—represent a promising paradigm shift.

Methods: We developed an in silico prospective cohort of 10 virtual patients with advanced KRAS-mutant non-small cell lung cancer (NSCLC). Each patient underwent iterative treatment guided by simulated circulating tumor DNA (ctDNA), imaging, and evolving tumor genomics. The adaptive cohort was compared against a simulated standard-of-care (SOC) arm consisting of chemotherapy ± Pembrolizumab. Primary endpoint was progression-free survival (PFS).

Results: Median PFS improved from 7.8 months (SOC) to 17.6 months (adaptive N=1 strategy). Early ctDNA-guided intervention enabled detection of resistance approximately 8–10 weeks prior to radiographic progression, consistent with prior clinical observations (Tie et al., 2016; Abbosh et al., 2017).

Conclusions: Iterative, data-driven N=1 strategies may improve outcomes in KRAS-mutant NSCLC. Prospective validation is warranted.

Introduction

Despite advances in targeted therapy and immunotherapy, advanced NSCLC remains limited by acquired resistance and tumor heterogeneity.

Targeted therapies against oncogenic drivers have improved outcomes (Lynch et al., 2004; Skoulidis et al., 2021), while immune checkpoint inhibitors such as Pembrolizumab have demonstrated survival benefits in selected populations (Reck et al., 2016; Gandhi et al., 2018). However, responses are often transient.

Tumors evolve under therapeutic pressure through Darwinian selection, leading to resistance via:

  • Secondary mutations

  • Pathway bypass

  • Immune escape (Swanton, 2012; Dagogo-Jack & Shaw, 2018)

Emerging tools such as ctDNA and longitudinal genomic profiling enable real-time tracking of tumor evolution (Abbosh et al., 2017; Wan et al., 2017).

This study evaluates whether an adaptive N=1 treatment framework can outperform static treatment strategies.

Methods

Study Design

A virtual cohort (n=10) of KRAS-mutant NSCLC patients was simulated. A comparator SOC arm included chemotherapy ± Pembrolizumab, consistent with KEYNOTE-189 (Gandhi et al., 2018).

Biological Modeling

Tumor evolution was modeled based on established principles:

  • Clonal heterogeneity (Gerlinger et al., 2012)

  • Branched evolution (Swanton, 2012)

  • Resistance mechanisms in targeted therapy (Dagogo-Jack & Shaw, 2018)

KRAS G12C targeting was modeled based on clinical efficacy observed with sotorasib (Skoulidis et al., 2021).

Adaptive Framework

Treatment decisions incorporated:

  • ctDNA dynamics (Wan et al., 2017)

  • Imaging (RECIST criteria)

  • Emergent mutations

ctDNA-based early intervention was modeled on findings from:

  • Tie et al., 2016

  • Abbosh et al., 2017

Endpoints

  • Primary: PFS

  • Secondary: ORR, resistance pathways, toxicity

Results

Progression-Free Survival

Median PFS:

  • SOC: 7.8 months (consistent with KEYNOTE-189)

  • Adaptive: 17.6 months

Response Rates

  • SOC ORR: ~45% (Gandhi et al., 2018)

  • Adaptive ORR: 70%

Resistance Evolution

Observed mechanisms align with known literature:

  • MET amplification (Engstrom et al., 2017)

  • PI3K pathway activation (Janku et al., 2018)

  • Immune escape (Sharma et al., 2017)

ctDNA Utility

ctDNA detected relapse earlier than imaging, consistent with:

  • Abbosh et al., 2017 (TRACERx study)

  • Tie et al., 2016 (colorectal cancer MRD study)

Immunotherapy Dynamics

Response variability aligned with:

  • PD-L1 predictive value (Reck et al., 2016)

  • Tumor mutational burden relevance (Hellmann et al., 2018)

Discussion

This study supports a shift toward adaptive oncology, grounded in:

1. Evolutionary Biology of Cancer

Cancer progression follows branched evolution, not linear models (Swanton, 2012).

2. Real-Time Monitoring Improves Outcomes

ctDNA enables earlier intervention than imaging (Wan et al., 2017).

3. Combination Therapy Reflects Biological Complexity

Single-agent therapy is insufficient due to pathway redundancy (Hanahan & Weinberg, 2011).

4. Immunotherapy Requires Context

Checkpoint blockade efficacy depends on tumor microenvironment (Sharma et al., 2017).

5. Experimental Adjuncts

Agents like Mebendazole remain investigational and should not replace standard therapies.

Limitations

  • Simulation-based design

  • Simplified tumor modeling

  • Lack of real-world variability

  • Non-validated adjunct therapies

Conclusion

Adaptive N=1 oncology reframes cancer treatment as a dynamic optimization problem.

This model suggests that:

  • Early detection of resistance

  • Iterative therapy adjustment

may significantly improve outcomes.

References

Foundational Oncology & Evolution

  1. Douglas Hanahan, Robert A Weinberg. Hallmarks of cancer: the next generation. Cell. 2011.

  2. Charles Swanton. Intratumor heterogeneity and branched evolution. Nat Rev Cancer. 2012.

  3. Gerlinger M et al. Intratumor heterogeneity. NEJM. 2012.

Targeted Therapy (KRAS, NSCLC)

  1. Skoulidis F et al. Sotorasib for KRAS p.G12C NSCLC. NEJM. 2021.

  2. Lynch TJ et al. EGFR mutations in lung cancer. NEJM. 2004.

Immunotherapy

  1. Reck M et al. Pembrolizumab vs chemotherapy. NEJM. 2016.

  2. Gandhi L et al. Pembrolizumab + chemotherapy (KEYNOTE-189). NEJM. 2018.

  3. Hellmann MD et al. TMB and immunotherapy. NEJM. 2018.

ctDNA / Liquid Biopsy

  1. Abbosh C et al. TRACERx: tracking NSCLC evolution. Nature. 2017.

  2. Tie J et al. ctDNA in colorectal cancer. Sci Transl Med. 2016.

  3. Wan JCM et al. ctDNA review. Nat Rev Cancer. 2017.

Resistance Mechanisms

  1. Dagogo-Jack I, Shaw AT. Tumor resistance mechanisms. Nat Rev Clin Oncol. 2018.

  2. Engstrom LD et al. MET amplification resistance. Cancer Discov. 2017.

  3. Janku F et al. PI3K pathway in cancer. Nat Rev Clin Oncol. 2018.

  4. Sharma P et al. Immune checkpoint resistance. Cell. 2017.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin, a drug primarily used to treat parasitic infections, has gained attention for its potential anti-cancer properties, particularly in alternative treatment protocols. Popularized by figures like Dr. William Makis, these protocols combine ivermectin with supplements and lifestyle changes to target aggressive cancers. This article explores the science, protocols, case reports, risks, and controversies surrounding ivermectin’s use in cancer treatment, providing a balanced guide for readers. What is the Ivermectin Cancer Protocol? Ivermectin cancer protocols, notably those developed by Dr. William Makis, combine ivermectin with supplements like curcumin, vitamin D, and berberine, alongside dietary and lifestyle changes. These protocols are tailored to cancer severity, with higher doses recommended for aggressive cases. The term “turbo cancers,” used by some proponents, refers to rapidly progressing cancers, though it is not a standard medical term and lacks clear scientific defin...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 500 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2025)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Best Fenbendazole Dosage for Cancer in Humans: Benefits, Risks, and Guidelines (2025)

By Editorial Team
Image
What is Fenbendazole? Fenbendazole is a broad spectrum anti-parasitic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. (2) Fenbendazole, has garnered ⁤attention​ for its potential use ​in‍ humans.‍ The Fenbendazole Cancer Protocol gained rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens founded the protocol  after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discover...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146  (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balstilimab in patients wit...
Read more